Jason Hawthorne (Repligen): Repligen might fly under the radar, but it serves an important role in a fast-growing industry. The stock price reinforces that. The company has benefited from the adoption of biologic drugs over traditional small-molecule chemical compounds.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting